// App-Quantinova.ai

AB0568 : BASELINE EUROPEAN PATIENT DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN A PHASE 3 STUDY OF SAFETY AND EFFICACY OF LENABASUM, A CB2 AGONIST, IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS

Researchers

Presenter

  • C. Denton

Principal Investigators

  • B. Bloom

  • N. Dgetluck

  • B. White

  • R. Spiera

Medical Centers

  • Kings College London, London, United Kingdom

  • Corbus Pharmaceuticals, Inc., Norwood, United States

  • Hospital for Special Surgery Main Hospital, New York, United States of America

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Scleroderma

Biomarkers

  • N/A

Drug/Treatment

  • Ajulemic acid

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • GSK plc

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved